Profile
Nick Maishman currently works as a Chief Operating Officer at Virocell Biologics Ltd.
Nick Maishman active positions
Companies | Position | Start |
---|---|---|
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | Chief Operating Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Nick Maishman